2,3-哌嗪二羧酸(6ci,7ci,9ci) | 89601-09-2

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 中文名称: 2,3-哌嗪二羧酸(6ci,7ci,9ci)
• 英文名称: Piperazine-2,3-dicarboxylic acid
• 英文别名: pyrazine-2,3-dicarboxylic acid；piperazine-1,4-diium-2,3-dicarboxylate
• CAS: 89601-09-2
• 化学式: C₆H₁₀N₂O₄
• mdl: MFCD07787611
• 分子量: 174.156
• InChiKey: ZLSOKZQPVJYNKB-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -6.2
• 重原子数：
  12
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.666
• 拓扑面积：
  98.7
• 氢给体数：
  4
• 氢受体数：
  6

安全信息

• 海关编码：
  2933599090

反应信息

• 作为反应物：
  描述：

  甲醇 、 2,3-哌嗪二羧酸(6ci,7ci,9ci) 在 硫酸 作用下， 以 甲醇 为溶剂， 反应 16.0h， 以47%的产率得到piperazine-2,3-dicarboxylic acid dimethyl ester
  参考文献：
  名称：

  [EN] PRE-ORGANIZED TRICYCLIC INTEGRASE INHIBITOR COMPOUNDS
  [FR] COMPOSÉS TRICYCLIQUES PRÉORGANISÉS INHIBITEURS D'INTÉGRASE

  摘要：

  公开号：

  WO2004035576A3
• 作为产物：
  描述：

  2,3-吡嗪二羧酸 在 palladium 10% on activated carbon 氢氧化钾 、 氢气 作用下， 以 水 为溶剂， 反应 16.0h， 生成 2,3-哌嗪二羧酸(6ci,7ci,9ci)
  参考文献：
  名称：

  Diamide compound and drugs containing the same

  摘要：

  本发明提供了以下一般式（1）所代表的二酰胺衍生物： 其中A是苯基或类似物，可以被取代，B是—CH═CH—，—C═C—，—(CH═CH)2—，—C≡C—CH═CH—，—CH═CH—C≡C—，苯基或类似物，W是 或 以及包含这种化合物的药物。这些化合物对IgE抗体的产生具有出色的抑制作用，因此可用作抗过敏药物等。

  公开号：

  US06340682B1

文献信息

• COSMETIC OR DERMATOLOGICAL COMPOSITION COMPRISING A POLYMER BEARING JUNCTION GROUPS, AND COSMETIC TREATMENT PROCESS
  申请人：Chodorowski-Kimmes Sandrine

  公开号：US20100239509A1

  公开（公告）日：2010-09-23

  The present patent application relates to a cosmetic or dermatological composition comprising, in a cosmetically or dermatologically acceptable medium, a polymer comprising: (a) a polymer backbone that may be obtained by reaction: of a polyol comprising 3 to 6 hydroxyl groups; of a monocarboxylic acid containing 6 to 32 carbon atoms; of a polycarboxylic acid comprising at least two carboxylic groups COOH, and/or of a cyclic anhydride such as a polycarboxylic acid and/or of a lactone comprising at least one carboxylic group COOH; and (b) at least one junction group linked to the said polymer backbone and capable of establishing H bonds with one or more partner junction groups, each pairing of a junction group involving at least three H (hydrogen) bonds. The patent application also concerns a cosmetic treatment process using the said composition.

  本专利申请涉及一种化妆品或皮肤科学组合物，包括在化妆品或皮肤科学上可接受的介质中，包含以下聚合物的组合物：(a) 由以下反应得到的聚合物骨架：含有3至6个羟基的多元醇；含有6至32个碳原子的一元羧酸；至少含有两个羧基COOH的多元羧酸，和/或类似多元羧酸的环酐和/或至少含有一个羧基COOH的内酯；以及(b) 至少一个连接到所述聚合物骨架的连接基团，并能够与一个或多个配对连接基团建立H键，每个连接基团的配对涉及至少三个H（氢）键。该专利申请还涉及使用所述组合物的化妆品处理过程。
• COMPOSITION COMPRISING A POLYCONDENSATE, METHOD OF TREATMENT, POLYCONDENSATE, AND METHOD OF PREPARATION
  申请人：GIUSTINIANI Pascal

  公开号：US20090028807A1

  公开（公告）日：2009-01-29

  The present application relates to a cosmetic or pharmaceutical, in particular lipstick, composition comprising a polycondensate The application also relates to a method of cosmetic treatment using the composition, the polycondensate thus defined and a method of preparing the polycondensate.

  本申请涉及一种化妆品或药用品，特别是口红，包括聚缩酸酯的组合物。该申请还涉及一种使用该组合物进行化妆处理的方法，所述聚缩酸酯的定义以及一种制备聚缩酸酯的方法。
• COSMETIC OR PHARMACEUTICAL COMPOSITION COMPRISING A POLYCONDENSATE, THE SAID POLYCONDENSATE AND METHOD OF COSMETIC TREATMENT
  申请人：Malle Gerard

  公开号：US20100272660A1

  公开（公告）日：2010-10-28

  The present application relates to a cosmetic or pharmaceutical composition comprising a polycondensate capable of being obtained by the reaction of the following monomers alone: of 10 to 30% by weight, relative to the total weight of the polycondensate, of one or more polyols comprising 3 to 6 hydroxyl groups; of 30 to 80% by weight, relative to the total weight of the polycondensate, of one or more linear, branched and/or cyclic, saturated or unsaturated, non-aromatic monocarboxylic acids comprising 6 to 32 carbon atoms; of 1 to 40% by weight, relative to the total weight of the polycondensate, of one or more polycarboxylic acids and/or cyclic anhydrides of such a polycarboxylic acid and/or lactones comprising at least one COOH group; and optionally of 0.1 to 15% by weight, relative to the total weight of the polycondensate, of one or more silicones having a hydroxyl and/or carboxyl functional group. The application also relates to a method of cosmetic treatment using the said composition, and the polycondensate thus defined.

  本申请涉及一种化妆品或药用组合物，包括由以下单体反应而得的聚缩酸酯：相对于聚缩酸酯的总重量，占10至30%的一种或多种含有3至6个羟基的多元醇；占30至80%的一种或多种线性、支链和/或环状、饱和或不饱和、非芳香族的单羧酸，含有6至32个碳原子；占聚缩酸酯总重量的1至40%的一种或多种多羧酸和/或多羧酸的环状酐和/或含有至少一个COOH基团的内酯；以及可选地占聚缩酸酯总重量的0.1至15%的一种或多种硅氧烷，具有羟基和/或羧基官能团。该申请还涉及使用所述组合物进行化妆处理的方法，以及如此定义的聚缩酸酯。
• Phenanthryl piperazinyl dicarboxylic acids as selective nmda receptor modulating agents
  申请人：——

  公开号：US20030078237A1

  公开（公告）日：2003-04-24

  Disclosed are compounds of formula (I) wherein: L is (a) optionally substituted by replacement of one or more of the hydrogen atoms on the phenanthrene ring system by one or more groups other than hydrogen; A is CH 2 , SO 2 or C═O; X is CO 2 H, PO 3 H 2 , PO 2 H 2 , PO 2 HR 5 , PO 2 HOR 5 , SO 3 H, SO 2 H, or tetrazole; and R 1 , R 2 , R 3 , R 4 and R 5 are independently selected from H, alkyl, alkenyl, alkynyl, aryl and aralkyl; or a pharmaceutically acceptable acid salt or base addition salt or an in vivo hydrolysable ester or amide thereof. Compounds of formula (I) are selective NMDA receptor modulating agents and, therefore, may be used to advantage in vitro in neuroassays and in vivo in the treatment of disorders of the CNS.

  公开了化合物的结构式(I)，其中：L是(a)通过将菲环上的一个或多个氢原子替换为一个或多个非氢基团而选择性地取代的；A是CH2，SO2或C═O；X是CO2H，PO3H2，PO2H2，PO2HR5，PO2HOR5，SO3H，SO2H或四唑；R1、R2、R3、R4和R5独立地选择自H、烷基、烯基、炔基、芳基和芳基烷基；或其药学上可接受的酸盐或碱加合盐或体内可水解的酯或酰胺。结构式(I)的化合物是选择性NMDA受体调节剂，因此，在神经分析中和中枢神经系统疾病的治疗中可以得到优势应用。
• Substituted piperazine-2-carboxylic acids and derivatives thereof
  申请人：British Technology Group Limited

  公开号：US05399693A1

  公开（公告）日：1995-03-21

  Compounds of the general formula ##STR1## wherein X is a C.sub.1 -C.sub.6, straight chain saturated or unsaturated hydrocarbyl group, the group R.sup.4 and the group Y are situated in any position in this chain and wherein at least one of the hydrogen atoms in X can be a heavy isotope of hydrogen; R.sup.4 is hydrogen or an alkyl, alkoxy, hydroxy, aryl, aryloxy, aralkyl, aralkoxy, aralkylamino, or morpholino group wherein the alkyl or aryl part of any one of said groups may be substituted by one or more halogeno groups; or R.sup.4, together with at least one carbon atom of the group X, forms a carbocyclic or heterocyclic ring of 5 to 6 ring atoms; Y is an acidic or related group giving rise to one or more electronegative sites in the group; or R.sup.4 --X--Y represents a carboxylic acyl group; R is hydrogen or an alkyl, haloalkyl, aryl, haloaryl, aralkyl or haloaralkyl; R.sup.1 is hydrogen or an alkyl, haloalkyl, aryl, haloaryl, aralkyl or haloaralkyl group; R.sup.2 R.sup.3 and R.sup.5 which may be the same or different is each hydrogen or an alkyl, hydroxy, alkoxy, carboxy, alkyloxycarbonyl, halo, aryl, haloaryl or aryloxycarbonyl group; or R.sup.2 and R.sup.3 together with the carbon atoms to which they are attached form a ring system or R.sup.3 and R.sup.4 together and/or R.sup.3 and X together form one or more than one ring systems, or a physiologically acceptable salt thereof have activity in the central nervous system.

  通式为##STR1##的化合物，其中X是C.sub.1-C.sub.6直链饱和或不饱和的烃基，基团R.sup.4和基团Y位于该链的任何位置，并且X中至少有一个氢原子可以是氘同位素；R.sup.4是氢或烷基、烷氧基、羟基、芳基、芳氧基、芳基烷基、芳基烷氧基、芳基烷基氨基或吗啉基团，其中上述任一群的烷基或芳基部分可能被一个或多个卤素基团取代；或者R.sup.4与基团X中的至少一个碳原子形成5到6个环原子的碳环或杂环；Y是一个酸性或相关的基团，在该基团中引起一个或多个电负性位点；或R.sup.4--X--Y代表一个羧酰基团；R是氢或烷基、卤代烷基、芳基、卤代芳基、芳基烷基或卤代芳基烷基；R.sup.1是氢或烷基、卤代烷基、芳基、卤代芳基、芳基烷基或卤代芳基烷基基团；R.sup.2、R.sup.3和R.sup.5，它们可以相同也可以不同，每个是氢或烷基、羟基、烷氧基、羧基、烷氧羰基、卤素、芳基、卤代芳基或芳氧羰基基团；或R.sup.2和R.sup.3与它们附着的碳原子一起形成一个环系统，或R.sup.3和R.sup.4一起和/或R.sup.3和X一起形成一个或多个环系统，或其生理上可接受的盐在中枢神经系统中具有活性。